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A redox switch in angiotensinogen 
modulates angiotensin release
Zhou et al., Nature advance online publication 6 October 2010, 
doi:10.1038/nature09505
Of the several hormonal systems involved in extracellular fluid 
and blood pressure control, the renin–angiotensin–aldosterone 
system (RAAS) is by far the best understood. Indeed, since the 
landmark experiments by Goldblatt showing that renal artery ste-
nosis increased blood pressure, the system has been used as an 
intellectual framework in the analysis of many other hormones. 
Further, our understanding of the RAAS has already borne fruit 
with the development of several compounds that inhibit its action 
and that have proven to be of invaluable therapeutic efficacy. 
Hence, the recent communication by Zhou et al. showing that a 
redox switch of angiotensinogen regulates angiotensin generation 
is an unexpected and exciting discovery. Angiotensinogen had 
long been considered a passive substrate, but when these work-
ers resolved its crystal structures to 2.1-Å resolution, they found 
that the angiotensin cleavage site was inaccessibly buried in its 
amino-terminal tail. However, a 4.4-Å structure of the complex 
of angiotensinogen with renin revealed the conformational rear-
rangement that makes the cleavage site accessible for proteolysis. 
Angiotensinogen from all species has two cysteines that are linked 
(Cys18–Cys138), and Zhou et al. found that this disulphide link-
age was labile and that the 18–138 bridge was broken in the crystal 
structure of reduced angiotensinogen. Although angiotensinogen 
is secreted in the oxidized bridged form, it is partially reduced by 
thiol-reductant systems in the plasma. Indeed, they found that 
both the reduced and the oxidized forms of angiotensinogen cir-
culate in plasma and do so with a remarkably consistent reduced-
to-oxidized proportion of about 40:60. To assess the functional 
consequences of the oxidative transition, they incubated the 
reduced and oxidized forms of angiotensinogen, renin, and the 
prorenin receptor and found that the presence of the prorenin 
receptor had little effect on the reduced form but increased the 
renin-binding affinity of the oxidized form, with a consequent 
fourfold increase in the catalytic release of angiotensin (Figure). 
An association of oxidative stress with hypertension as well as 
placental dysfunction has long been recognized, and thus they 
examined whether oxidative changes occurred in angiotensinogen 
in pre-eclampsia. They found that plasma samples from women 
with pre-eclampsia showed a decrease in reduced angiotensino-
gen and an increase in the oxidized form, suggesting a causative 
link between the oxidative changes in pregnancy and the onset 
of the hypertension. Thus, the release of angiotensin requires a 
change in conformation in angiotensinogen to allow the access 
and binding of renin, and central to this change is a labile disul-
phide bridge that readily undergoes a transition to a more active 
oxidized form. Needless to say, this elegant study will trigger a 
reevaluation of several long-standing and unexplained observa-
tions on the functioning of the RAAS.
Juan Oliver
PPAR-γ agonist rosiglitazone 
protects peritoneal membrane  
from dialysis fluid-induced damage
Sandoval et al., Lab Invest 2010; 90: 1517–1532; doi:10.1038/
labinvest.2010.111
Exposure to non-physiological solutions during peritoneal dialysis 
(PD) produces structural alterations to the peritoneal membrane 
and ultrafiltration dysfunction. The high concentration of glucose 
and glucose degradation products in standard PD fluids induces a 
local diabetic environment, leading to the formation of advanced 
glycation end products (AGEs) that have an important role in peri-
toneal membrane deterioration. Peroxisome proliferator-activated 
receptor-γ (PPAR-γ) is a member of the nuclear hormone receptor 
family that has a key role in the regulation of lipid and glucose 
homeostasis. Besides their glucose-lowering effects, PPAR-γ ago-
nists also have anti-inflammatory and antifibrotic properties by 
modulating both innate and adaptive immune responses and by 
activating a regulatory T-cell response. Sandoval and colleagues 
evaluated the efficacy and potential mechanisms of the PPAR-γ 
agonist rosiglitazone (RSG) in ameliorating peritoneal membrane 
damage in a mouse PD model. Administration of RSG diminished 
the accumulation of AGEs, preserved the mesothelial monolayer, 
decreased the number of invading mesothelial cells, reduced 
fibrosis and angiogenesis, and improved peritoneal function (Fig-
ure). Interestingly, instead of reducing the leukocyte recruitment, 
RSG administration enhanced this process, and specifically the 
recruitment of CD3+ lymphocytes. Furthermore, RSG treatment 
augmented the levels of the anti-inflammatory cytokine inter-
leukin-10 and increased the recruitment of CD4+ CD25+ FoxP3+ 
cells, suggesting that regulatory T cells mediated the protection of 
the peritoneal membrane. The protection offered by RSG is not 
related to changes in the activation of the adipose tissue (leptin 
levels were comparable in treated and untreated animals). A more 
refined characterization of the immunoinflammatory response in 
RSG-treated animals is necessary before a definitive mechanistic 
role can be ascribed to particular cells.
The study suggests that PPAR-γ activation might be a suitable 
strategy to ameliorate peritoneal deterioration in PD patients. 
Reactions of renin and angiotensinogen (oxidized and reduced, ‘-oxi’ 
and ‘-red’) in the presence or absence of prorenin receptor (PRR) with 
angiotensin I concentration.
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Although end-stage renal disease seems not to be a major 
problem from the pharmacokinetic point of view since RSG 
is metabolized in the liver, a number of well-documented side 
effects call for caution.
Marc De Broe
Further evidence that Toll-like  
receptors contribute to autoimmune 
disease with renal involvement
Demaria et al., J Clin Invest 2010; 120: 3651–3662; doi:10.1172/JCI42081
The role of Toll-like receptors (TLRs) in the innate immune 
response against pathogens is well established. In addition, TLRs 
also can recognize endogenous ‘danger’ molecules that are gener-
ated during cell stress and necrosis. In this context, TLRs may play 
a role in the dysregulation of the immune system that underlies 
autoimmune diseases. Thus, TLR7 and also TLR9 may contribute 
to systemic lupus erythematosus (SLE) and its renal manifesta-
tions. Among the various TLRs, the role of TLR8 was mostly 
unclear. Now, Demaria and co-workers identify a novel contribu-
tory role for TLR8 in regulation of the expression of TLR7, and 
thereby in the SLE-like disease related to overexpression of TLR7. 
They found that Tlr8–/– dendritic cells overexpressed TLR7, were 
hyperresponsive to various TLR7 ligands, and showed stronger 
and faster nuclear factor-κB activation upon stimulation with the 
TLR7 ligand R848. Tlr8–/– mice showed splenomegaly, defective 
development of marginal zone and B1 B cells, and increased 
serum levels of IgM and IgG2a. Furthermore, Tlr8–/– mice exhib-
ited increased serum levels of autoantibodies against small nuclear 
ribonucleoproteins, ribonucleoprotein, and double-stranded 
DNA and developed glomerular immune deposits, whereas nei-
ther Tlr7–/– nor Tlr8–/–Tlr7–/– mice showed any of the phenotypes 
observed in Tlr8–/– mice. These data provide evidence for a role 
for mouse TLR8 in the regulation of mouse TLR7 expression and 
prevention of spontaneous autoimmunity.
These results further strengthen the important role of TLR7 in 
autoimmune responses and show for the first time that TLR8 may 
also be involved, albeit in an indirect manner. Remaining un answered 
is how TLR8 controls TLR7 expression, and whether this might be 
related to potential heterodimer formation between TLR7 and TLR8. 
Thus, both TLR7 and TLR8 may be important in promoting auto-
antibody production and lupus disease development.
Detlef Schlöndorff
Severe hypoglycemia and risks  
of vascular events and death
Zoungas et al., N Engl J Med 2010; 363: 1410–1418
Although good blood sugar control has resulted in improved 
outcomes, recent trials suggest that extremely rigorous control 
may result in harm. A new secondary analysis of the Action in 
Diabetes and Vascular Disease: Preterax and Diamicron Modi-
fied Release Controlled Evaluation (ADVANCE) trial suggests 
that severe hypoglycemia may play a role. ADVANCE was a 
factorial trial assessing the efficacy of an antihypertensive as 
well as the effects of intensive glucose lowering with the use of 
a modified-release formulation of gliclazide as compared with 
standard glucose lowering on the risk of vascular outcomes and 
death among patients with type 2 diabetes. Hypoglycemia was 
defined as a blood glucose level of less than 50 mg/dl or the 
presence of typical symptoms of hypoglycemia. Severe hypogly-
cemia was defined as an episode of hypoglycemia accompanied 
by transient central nervous system dysfunction requiring help 
from another person. Over a follow-up of 5 years, more patients 
in the intensive-control group experienced severe hypoglycemic 
events (2.7% versus 1.5%). Episodes of severe hypoglycemia 
became increasingly common over time in patients undergoing 
intensive glucose control, whereas the rate of severe hypogly-
cemia remained stable in the group receiving standard treat-
ment. Patients reporting severe hypoglycemia had a greater risk 
of subsequent major macrovascular events than those who did 
not report severe hypoglycemia (16.8% versus 10.2%). The risk 
remains significant after adjustment for potential confounding 
variables measured at baseline and during follow-up. However, 
there was no evidence of a dose–response relationship between 
repeated episodes of severe hypoglycemia and vascular out-
comes or death. Also, there were no differences in the risk of 
death alone based on treatment arm between patients who did 
and did not experience severe hypoglycemia (hazard ratio 0.67, 
95% confidence interval 0.37–1.21; and hazard ratio 0.93, 95% 
confidence interval 0.82–1.06).
This study suggests the role of severe hypoglycemia as a poten-
tial mediator of the increased risks of cardiovascular outcomes 
other than death that have been demonstrated in trials look-
ing at the effect of intensive blood glucose control. While cause 
and effect cannot be definitively proven by these data, given the 
nature of the safety signal, the mechanism can only be examined 
in observational studies or secondary analyses of completed 
trials. If this hypothesis is true, it will become increasingly 
important for clinical focus on the metabolism of hypoglycemic 
agents in those with impaired kidney function who may be at 
greater risk for these events.
Lynda Szczech 
Rosiglitazone (RSG) treatment decreases PD-induced peritoneal 
membrane thickness in a mouse model. PDF, PD fluid.
